SEC 13F Intelligence

Managers / Q1 2026

Rock Springs Capital Management LP

CIK 0001595725 · 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE, MD, 21202 · 4102200129

Reported Value
$1.7B
Q1 2026
Positions
100
Filings on Record
30
2019–present window
Filed
May 15, 2026
original filing

Summary

Rock Springs Capital Management LP reported $1.7B in U.S.-listed holdings across 100 positions for Q1 2026.

Its largest position, RVMD, represents 6.9% of the portfolio.

Compared with Q4 2025, the fund opened 11 new positions and exited 9.

Portfolio Metrics

Turnover
+10.8%
vs prior filed quarter
Top-10 Concentration
+40.6%
share of reported value
Largest Position
+6.9%
Revolution Medicines
New / Exited
11 / 9
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.1BQ4 ’18Q1 ’19: $2.6BQ2 ’19: $2.8BQ3 ’19: $2.5BQ4 ’19: $3.2BQ4 ’19Q1 ’20: $2.4BQ2 ’20: $3.6BQ3 ’20: $3.9BQ4 ’20: $4.7BQ4 ’20Q1 ’21: $4.6BQ2 ’21: $5.1BQ3 ’21: $4.8BQ4 ’21: $4.3BQ4 ’21Q1 ’22: $4.0BQ2 ’22: $3.4BQ3 ’22: $3.9BQ4 ’22: $4.2BQ4 ’22Q1 ’23: $4.2BQ2 ’23: $4.2BQ3 ’23: $3.7BQ4 ’23: $4.1BQ4 ’23Q1 ’24: $3.9BQ2 ’24: $3.3BQ3 ’24: $3.1BQ4 ’24: $2.6BQ4 ’24Q1 ’25: $1.7BQ2 ’25: $1.6BQ3 ’25: $1.7BQ4 ’25: $2.0BQ4 ’25Q1 ’26: $1.7Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 86.0%ADR: 8.4%Other: 5.4%ETP: 0.2%
  • Common Stock · 86.0% · $1.5B
  • ADR · 8.4% · $143M
  • Other · 5.4% · $92M
  • ETP · 0.2% · $4M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MMEDMINIMED GROUP INCNEW+1.05M1.05M+$16M$16M
INDVINDIVIOR PHARMACEUTICALS INCNEW+200.0K200.0K+$6M$6M
SYKSTRYKER CORPORATIONNEW+14.8K14.8K+$5M$5M
NVONOVO-NORDISK A SNEW+90.0K90.0K+$3M$3M
VKTXVIKING THERAPEUTICS INCNEW+96.0K96.0K+$3M$3M
IPSCCENTURY THERAPEUTICS INCNEW+1.30M1.30M+$3M$3M
CVSCVS HEALTH CORPNEW+40.0K40.0K+$3M$3M
DNTHDIANTHUS THERAPEUTICS INCNEW+26.8K26.8K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RVMDREVOLUTION MEDICINES INChistory →COM6.93%$118M1.21M
2LLYELI LILLY & COhistory →COM5.35%$91M98.7K
3MDGLMADRIGAL PHARMACEUTICALS INChistory →COM5.28%$90M171.0K
4MIRMMIRUM PHARMACEUTICALS INChistory →COM4.42%$75M811.3K
5ARGXARGENX SEhistory →SPONSORED ADR4.24%$72M98.5K
6RYTMRHYTHM PHARMACEUTICALS INChistory →COM3.54%$60M689.7K
7IM8NINSMED INChistory →COM PAR $.013.03%$51M314.3K
8ASCENDIS PHARMA A/SSPONSORED ADR2.62%$44M194.0K
9XENEXENON PHARMACEUTICALS INChistory →COM2.62%$44M763.0K
10TVTXTRAVERE THERAPEUTICS INChistory →COM2.59%$44M1.48M
11KYMRKYMERA THERAPEUTICS INChistory →COM2.44%$41M496.9K
12PENPENUMBRA INChistory →COM2.33%$40M120.5K
13ISRGINTUITIVE SURGICAL INChistory →COM NEW2.23%$38M82.0K
14SRRKSCHOLAR ROCK HLDG CORPhistory →COM2.14%$36M739.8K
15ELVNENLIVEN THERAPEUTICS INChistory →COM1.91%$32M826.5K
16BSXBOSTON SCIENTIFIC CORPhistory →COM1.91%$32M515.3K
17IRTCIRHYTHM HOLDINGS INChistory →COM1.82%$31M261.8K
18GPCRSTRUCTURE THERAPEUTICS INChistory →SPONSORED ADS1.82%$31M640.2K
19AGIOAGIOS PHARMACEUTICALS INChistory →COM1.59%$27M799.2K
20RAREULTRAGENYX PHARMACEUTICAL INhistory →COM1.50%$26M1.22M
21ALNYALNYLAM PHARMACEUTICALS INChistory →COM1.44%$24M74.0K
22COGTCOGENT BIOSCIENCES INChistory →COM1.42%$24M624.2K
23THCTENET HEALTHCARE CORPhistory →COM NEW1.39%$24M125.0K
24DC4DEXCOM INChistory →COM1.32%$22M355.6K
25TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW1.22%$21M650.3K
26VERAVERA THERAPEUTICS INChistory →CL A1.19%$20M503.6K
27NBIXNEUROCRINE BIOSCIENCES INChistory →COM1.17%$20M150.4K
28ACLXGBXARCELLX INChistory →COMMON STOCK1.15%$20M169.9K
29NEWAMSTERDAM PHARMA COMPANYORDINARY SHARES1.11%$19M588.8K
30PHARVARIS N VCOM1.07%$18M645.5K
31ERASERASCA INChistory →COM1.05%$18M1.10M
32DYNDYNE THERAPEUTICS INChistory →COM1.04%$18M972.2K
33CMPXCOMPASS THERAPEUTICS INChistory →COM1.03%$17M3.31M
34ACRSACLARIS THERAPEUTICS INChistory →COM0.99%$17M4.47M
35TARSTARSUS PHARMACEUTICALS INChistory →COM0.93%$16M225.2K
36MMEDMINIMED GROUP INChistory →COM0.93%$16M1.05M
37ZLABZAI LAB LTDhistory →ADR0.90%$15M814.7K
38UNHUNITEDHEALTH GROUP INChistory →COM0.85%$14M53.0K
39260CENTESSA PHARMACEUTICALS PLChistory →SPONSORED ADS0.82%$14M351.8K
40HTFLHEARTFLOW INChistory →COM0.82%$14M572.5K
41ARDXARDELYX INChistory →COM0.81%$14M2.30M
42SMMTSUMMIT THERAPEUTICS INChistory →COM0.79%$13M710.0K
43AZTAAZENTA INChistory →COM0.71%$12M569.1K
44MLYSMINERALYS THERAPEUTICS INChistory →COM0.70%$12M439.8K
45DHRDANAHER CORP DELhistory →COM0.69%$12M61.5K
46PTCTPTC THERAPEUTICS INChistory →COM0.65%$11M161.8K
47CAICARIS LIFE SCIENCES INChistory →COM0.59%$10M563.0K
48ZBIOZENAS BIOPHARMA INCCOM0.58%$10M502.1K
49BCAXBICARA THERAPEUTICS INCCOM0.57%$10M489.1K
50BBIOBRIDGEBIO PHARMA INCCOM0.56%$10M128.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.7B100May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.0B99Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.7B93Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.6B93Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.7B96May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$2.6B107Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$3.1B109Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$3.3B112Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$3.9B114May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$4.1B104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$3.7B120Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$4.2B123Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$4.2B121May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$4.2B120Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$3.9B128Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$3.4B131Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$4.0B135May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$4.3B136Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$4.8B153Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$5.1B156Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$4.6B151May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$4.7B155Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$3.9B148Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$3.6B143Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.4B131May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$3.2B130Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$2.5B138Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.8B135Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.6B131May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.1B133Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.